Pharmacoclinical strategy in neuroleptic resistant schizophrenic patients treated by clozapine: Clinical evolution, concentration of plasma and red blood cell clozapine and desmethylclozapine, whole blood serotonin and tryptophan

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 23, Issue 1, 1999, Pages 25-41

  Aymard, Nicole ^a,b   Viala, Annie ^a   Baldacci, Chantal ^a   Smagghe, Pierre Olivier ^a   Vacheron, Marie Noelle ^a   Caroli, Francois ^a  

^a CENTRE HOSPITALIER SAINTE ANNE   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Atypical neuroleptic; Clinical correlations; Clozapine; Fluoxetine; Plasma; Red blood cells; Refractory schizophrenia; Serotonin

Indexed keywords

CLOZAPINE; FLUOXETINE; NORCLOZAPINE; NORFLUOXETINE; SEROTONIN; TRYPTOPHAN;

ADULT; AGRANULOCYTOSIS; ARTICLE; CLINICAL ARTICLE; CORRELATION FUNCTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MONITORING; FEMALE; HUMAN; MALE; PATIENT COMPLIANCE; SCHIZOPHRENIA; SEIZURE;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIPSYCHOTIC AGENTS; BRIEF PSYCHIATRIC RATING SCALE; CLOZAPINE; DEPRESSIVE DISORDER; DRUG MONITORING; FEMALE; FLUOXETINE; HUMANS; MALE; MIDDLE AGED; SCHIZOPHRENIA; SEROTONIN; TRYPTOPHAN;

EID: 0033020254     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-5846(98)00089-X     Document Type: Article

References (34)

1. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders, 4th Ed.
2. Aymard, N., Renouard, C., Leyris, A. and Carbuccia, I. (1993) Intérêt de la détermination des concentrations intra-érythrocytaires des antidépresseurs tricycliques, tétracycliques et de leurs dérivés déméthylés. Biologie Prospective. Compte-rendu du 8ème colloque de Pont à Mousson. John Libbey Eurotext: Paris; 191-194.
3. Aymard, N., Honore, P. and Carbuccia, I. (1994) Determination of 5- hydroxytryptamine and tryptophan by liquid chromatography in whole blood. Its interest for the exploration of mental disorders. Prog. Neuro-psychopharmacol. & Biol. Psychiat. 18: 77-86.
4. Aymard, N., Viala, A., Stein, I. and Caroli, F. (1995) Pharmacoclinical correlations in schizophrenic patients treated with haloperidol decanoate: Clinical evaluations, concentrations of plasma and red blood cell haloperidol and its reduced metabolite, and plasma homovanillic acid. Prog. Neuro-psychopharmacol. & Biol. Psychiat., 19: 1119-1135.
5. Aymard, N., Baldacci, C., Leyris, A., Smagghe, P.O., Tribolet, S., Vacheron, M.N., Viala, A. and Caroli, F. (1997) Neuroleptic-resistant schizophrenic patients treated by clozapine: Clinical evolution, plasma and red blood cell clozapine and desmethylclozapine levels. Therapie, 52: 227-232.
6. Breier, A. (1995) Serotonin, schizophrenia and antipsychotic drug action. Schizophrenia Research, 14: 187-202.
7. Carlsson, A. (1995) Neurocircuities and neurotransmitter interactions in schizophrenia. Int. Clin. Psychopharmacol., 10: (suppl.3): 21-28.
8. Chong, S.A., Tan, C.H., Khoo, Y.M., Lee, H.S., Wong, K.E., Ngui, F. and Winslow, M. (1997) Clinical evaluation and plasma clozapine concentrations in chinese patients with schizophrenia. Ther. Drug Monit., 19: 219-223.
9. Conley, R.R., Carpenter, W.T. and Tamminga, C. (1997) Time to clozapine response in a standardized trial. Am. J; Psychiatry, 154 (9): 1243-1247.
10. Evins, A.E. and Goff, D.C. (1996) Adjunctive antidepressant drug therapies in the treatment of negative symptoms of schizophrenia. CNS Drug, 2: 130-147.
11. Freeman, D.J. and Oyewumi, K. (1997) Will routine therapeutic drug monitoring have a place in clozapine therapy? Clin. Pharmacokinet., 32 (2): 93-100.
12. Hasegawa, M., Gutierrez-Esteinou, R., Way, L. and Meltzer, H.Y. (1993) Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: Effect of smoking. Psychopharmacology (Berl), 10: 799-812.
13. Hasegawa, M., Cola, P.A. and Meltzer, H.Y. (1994) Plasma clozapine and desmethylclozapine levels in clozapine-induced agranulocytosis. Neuropsychopharmacology, 11(n°1): 45-47.
14. Heinrich, C.W., Hanlon, T.E. and Carpenter, W.T. (1984) The quality of life scale: An instrument for rating the schizophrenic deficit syndrome. Schizophrenia Bull., 3: 388-396.
15. Iqbal, N. and Van Praag, G. (1995) The role of serotonin in schizophrenia. Eur. Neuropsychopharmacol., suppl.: 11-23.
16. Kane, J.M. (1997) The use of scales for clinical monitoring of disease progression and the treatment of schizophrenia. Neuropsychobiology, 35: 64-66.
17. Kapur, S. and Remington, G. (1996) Serotonin-dopamine interaction and its relevance to schizophrenia. Am. J. Psychiatry, 153 (4): 466-476.
18. Ko, G.N., Korpi, E.R. and Kirch, D.G. (1989) Haloperidol and reduced haloperidol concentrations in plasma and red blood cells from schizophrenic patients. J. Clin. Psychopharmacol., 9: 186-190.
19. Kronig, M.H., Munne, R.A. and Szymanski, S. (1995) Plasma clozapine levels and clinical response for treatment refractory schizophrenic patients. Am. J. Psychiatry, 152: 799-812.
20. Laruelle, M., Abi-Dargham, A., Casanova, M.F. and Toti, R. (1993) Selective abnormalities of prefrontal serotonergic receptors in schizophrenia. Arch. Gen. Psychiatry, 50: 810-818.
21. Lin, S.K., Chang, W.H., Chung, M.C., Lam, Y.W.F. and Jann, M.W. (1994) Disposition of clozapine and desmethylclozapine in schizophrenic patients. J. Clin. Pharmacol., 34: 318-324.
22. Lundberg, T., Lindström, L., Hartvig, P., Reibring, L., Agren, H., Lundqvist, H., Fasth, K., Antoni, G. and Langström, B. (1996) Serotonin-2 and dopamine-1 binding components of clozapine in frontal cortex and striatum in the human brain visualized by positron emission tomography. Psychiatry Research: Neuroimaging, 67: 1-10.
23. Meijer, J.W.A. and Driessen, O. (1990) Role of erythrocytes in the early phase of drug distribution; an element of chronopharmacology? in: Dreifuss F., Meinardi H.S.,eds. Chronopharmacology in Therapy of the Epilepsies. New York: Raven Press Ltd.
24. Naber, D., Holzbach R,., Perro, C. and Hippius, H. (1992) Clinical management of clozapine patients in relation to efficacy and side effects. Br. J. Psychiatry, 160 (suppl. 17): 54-59.
25. Nakaya, M., Ohmori, K., Komahashi, T. and Suwa, H. (1997) Depressive symptoms in acute schizophrenic inpatients. Schizophrenia Research, 25: 131-139.
26. Olesen, O.V., Thomsen, K. and Jensen, P.N. (1995) Clozapine serum levels and side effects during steady state treatment of schizophrenic patients: A cross sectional study. Psychopharmacology, 117: 871-878.
27. Peacock, L. and Gerlach, J. (1994) Clozapine treatment in denmark: Concomittant psychotropic medication and hematologic monitoring in a system with liberal usage pratices. J. Clin. Psychiatry, 55: 44-49.
28. Perry, P.J., Miller, D.D., Arndt, S.V. and Cadoret, R.J. (1991) Clozapine and norclozapine plasma concentrations and clinical response of treatment refractory schizophrenic patients. Am. J. Psychiatry, 148: 231-235.
29. Pickar, D. (1995) Prospects for pharmacotherapy of schizophrenia. The Lancet, 345 (8949): 557-562.
30. Rietschel, M., Naber, D., Fimmers, R., Möller, H.J., Propping, P. and Nöthen, M.M. (1997) Efficacy and side-effects of clozapine not associated with variation in the 5-HT2C receptor. NeuroReport, 8: 1999-2003.
31. Shulz, E., Fleischhaker, C., Clement, H.W. and Remschmidt, H. (1997) Blood biogenic amines during clozapine treatment of early-onset schizophrenia. J. Neural Transm., 104: 1077-1089.
32. Sumiyoshi, T., Hasegawa, M., Jayathilake, K. and Meltzer, H.Y. (1997) Prediction of short-term changes in symptom severity by baseline plasma homovanillic acid levels in schizophrenic patients receiving clozapine. Psychiat. Res., 69: 113-121
33. Thomare, P., Wang, K. and Van der Meersch, V. (1992) Sensitive micromethod for column liquid chromatographie determination of fluoxetine and norfluoxetine in human plasma. J. Chromatogr., 583: 217-221.
34. Vatassery, G.T., Herzan, L.A. and Kysken, M.W. (1990) Liquid chromatographic determination of reduced haloperidol and haloperidol concentrations in packed red blood cells from humans. J. Anal. Toxicol. 14: 25-27.